Browse the evidence

Obesity and overweight status are strongly associated with higher odds of dyslipidemia in Iranian adults, with obese individuals having 2.8 times higher risk compared to normal-weight adults.

Maintaining a healthy weight is crucial for managing blood lipids. In this population, obesity significantly increases the risk of dyslipidemia. Focus on sustainable lifestyle changes including balanced nutrition and regular physical activity to manage weight and improve lipid profiles.

Physical inactivity is associated with increased odds of dyslipidemia, with inappropriate physical activity increasing the odds by 1.2 times compared to appropriate activity.

Regular physical activity helps manage blood lipids. This study found that those with inappropriate physical activity had higher odds of dyslipidemia. Aim for regular moderate-to-vigorous physical activity as part of a healthy lifestyle.

Ultra rapid lispro (URLi) administered as a bolus with basal insulin improves postprandial glucose excursions (PPGE) after breakfast more effectively than standard insulin lispro in adults with type 2 diabetes, while maintaining non-inferior HbA1c reduction and similar safety profiles regarding hypoglycemia and weight gain.

If you have Type 2 Diabetes and struggle with high blood sugar after meals, especially breakfast, ask your doctor about Ultra Rapid Lispro (URLi). It is taken exactly like your current rapid-acting insulin (just before eating) but absorbs faster to better match your food. This can significantly reduce the sharp blood sugar spikes after breakfast without increasing your risk of low blood sugar or weight gain compared to standard insulin lispro.

Higher intake of ultra-processed foods is associated with a significantly increased risk of developing inflammatory bowel disease (IBD), including both Crohn's disease and ulcerative colitis.

To lower your risk of inflammatory bowel disease, focus on reducing ultra-processed foods. This includes soft drinks, refined sweetened foods (candy, pastries), salty snacks, and processed meats. You do not need to avoid natural foods like meat, dairy, or vegetables, as the study found no link between those and IBD risk. The key is minimizing items with additives and preservatives, which may disrupt gut health.

High consumption of long-chain omega-3 fatty acids is associated with a significantly lower risk of developing laparoscopically confirmed endometriosis.

Focus on increasing intake of long-chain omega-3 fatty acids, primarily found in fatty fish (like tuna and dark fish) and certain salad dressings, as higher consumption is linked to a lower risk of endometriosis in large prospective studies. This does not mean avoiding all fats, as total fat intake showed no association, but rather prioritizing specific beneficial fatty acids.

Mathematical models of body weight regulation show that the caloric equivalent of lost weight is not constant but depends nonlinearly on initial body fat mass.

The number of calories you need to cut to lose a pound of weight changes as you lose weight, especially if you start with a higher body fat percentage. Fatter individuals need to create a larger caloric deficit to lose the same amount of weight compared to leaner individuals.

Systematic evidence mapping of human intervention studies reveals that specific fiber types (e.g., guar gum, psyllium) and physiological health outcomes (e.g., LDL cholesterol, postprandial glycemia) are well-documented, whereas gaps exist for other fiber-outcome pairings.

To target specific health goals like lowering cholesterol or managing blood sugar, look for supplements or foods containing specific, well-studied fibers like psyllium or guar gum, rather than generic 'fiber' blends. The database highlights that evidence strength varies significantly by fiber type.

Indian populations have a higher susceptibility to type 2 diabetes at lower body mass indices (BMI) compared to global averages.

If you are of Indian descent, be aware that you may be at risk for diabetes even if you have a normal BMI. Prioritize regular screening and maintain a healthy lifestyle to manage risk factors.

Metformin is the preferred initial oral hypoglycemic monotherapy for type 2 diabetes due to its efficacy, safety, and low risk of hypoglycemia and weight gain.

Start with metformin as your first medication if lifestyle changes alone aren't enough. It is the standard because it works well, is safe long-term, and rarely causes low blood sugar or weight gain. If your blood sugar isn't controlled, your doctor will add another medication.

If metformin is contraindicated or not tolerated, other oral hypoglycemic agents (DPP4 inhibitors, SGLT2 inhibitors, Sulfonylureas, etc.) can be used as initial monotherapy based on clinical situation.

If you can't take metformin, your doctor will choose another medication based on your specific health needs, such as kidney function or heart risk. Options include DPP4 inhibitors, SGLT2 inhibitors, or others.

Among pharmacotherapies, Semaglutide 2.4 mg and Orlistat have the most favorable safety/tolerability profiles, while Liraglutide 3.0 mg has the least tolerability, and Tirzepatide has intermediate tolerability.

When choosing a weight loss medication, be aware that tolerability varies. Semaglutide and Orlistat tend to be better tolerated, while Liraglutide may cause more side effects. Tirzepatide, despite its high efficacy, has intermediate tolerability, meaning you might experience more side effects than with Semaglutide or Orlistat.

A low-carbohydrate, high-protein, high-fat diet produces greater short-term weight loss (up to 6 months) than a conventional low-calorie, high-carbohydrate diet, but this advantage disappears by 12 months.

If you switch to a low-carb diet, expect faster weight loss in the first 6 months compared to a standard low-fat diet, but don't assume it will stay superior after a year. The initial boost likely comes from reduced calorie intake rather than a magical metabolic shift. To maintain results long-term, you likely need more than just a diet book; consider adding structured support or behavioral strategies to prevent the common drop-off seen in self-directed diets.

A low-carbohydrate diet improves cardiovascular risk markers (specifically HDL cholesterol and triglycerides) more effectively than a conventional diet, even when weight loss differences are accounted for.

Switching to a low-carb diet can significantly improve your HDL ('good') cholesterol and lower triglycerides more than a standard low-fat diet. While LDL cholesterol might rise initially, it often stabilizes over time. This suggests that focusing solely on fat intake might be less important than the overall macronutrient balance and its effect on your lipid profile.

Fat cell size (FCS) is the strongest independent determinant of baseline insulin sensitivity in overweight subjects, and its reduction is correlated with improved insulin sensitivity, although it is not an independent predictor of Si improvement after weight loss.

While losing visceral fat is key for improving insulin sensitivity, the health of your subcutaneous fat cells (their size) is a major factor in your baseline metabolic state. Large fat cells are associated with insulin resistance. Weight loss reduces fat cell size, which is part of the mechanism for improved health, though the total amount of fat lost (especially visceral) is the primary driver of the improvement.

Orlistat provides only marginal additional weight loss when used as a 'toolbox' option for participants who have lost less than 5% of their initial weight after 6 months of intensive lifestyle intervention.

If you are using orlistat, understand it is a supplementary tool, not a primary solution. It offers only marginal additional weight loss for those who have not yet achieved significant weight loss through lifestyle changes. Prioritize lifestyle adherence first.

Sustained moderate-intensity exercise (approx. 2000 kcal/week) prevents weight gain in young overweight women but produces significant fat loss in young overweight men over 16 months, independent of dietary changes.

If you are young and overweight, committing to about 45 minutes of moderate exercise (like brisk walking or cycling) five days a week will likely keep you from gaining weight. Men in this study actually lost significant fat, while women maintained their weight while sedentary controls gained. Do not expect rapid weight loss if you do not change your diet, but expect significant long-term health and composition benefits compared to doing nothing.

Combining the amylin analog pramlintide with the leptin analog metreleptin produces significantly greater weight loss in obese humans than either agent alone, primarily by synergistically enhancing fat loss and mitigating metabolic counter-regulation.

For obese or overweight individuals without diabetes, combining pramlintide and metreleptin offers significantly better weight loss than using either drug alone. The regimen involves twice-daily subcutaneous injections taken before meals, alongside a moderate caloric deficit. While side effects like nausea and injection site reactions occur, they tend to be mild and diminish over time. This approach is particularly useful for those who experience weight loss plateaus with standard therapies.

Low-carbohydrate diets produce greater weight loss, improved HDL, and lower triglycerides compared to low-fat diets over 6-12 months, but result in higher LDL and total cholesterol levels.

If you are choosing between low-carb and low-fat for weight loss, low-carb diets tend to yield slightly better results (about 1.3 kg more loss) and improve triglycerides and HDL more effectively over 6-12 months. However, be aware that low-carb diets may raise LDL and total cholesterol. If you have high baseline LDL, a low-fat diet might be safer for your lipid profile, even if weight loss is slightly less. Monitor your lipids regardless of the diet chosen.

Lorcaserin (10 mg twice daily) reduces body weight in overweight/obese adults primarily by decreasing energy intake, with no significant effect on energy expenditure or substrate oxidation.

Take lorcaserin (10 mg, twice daily) as prescribed. It works by reducing your appetite and energy intake, not by speeding up your metabolism. Expect weight loss to be driven by eating less, and understand that your body's energy expenditure will naturally decrease as you lose weight, which is a normal metabolic adaptation, not a failure of the drug.

Improvements in insulin sensitivity (HOMA-IR) and intrahepatic lipid content during caloric restriction are transient and not maintained during the weight maintenance phase, unlike other cardiometabolic markers.

Be aware that while caloric restriction improves insulin sensitivity during the weight loss phase, this specific benefit may not persist once you stop losing weight, even if you maintain the lower calorie intake. Other cardiovascular benefits, like lower blood pressure and better cholesterol, do persist. This suggests that maintaining a healthy weight and diet is crucial, but you might need additional strategies (like exercise or specific dietary components) to sustain insulin sensitivity improvements long-term.

Accurate quantification of energy intake and percent calorie restriction during weight loss requires measuring total energy expenditure (TEE) within the first 2–4 weeks of intervention to capture the rapid decline in metabolic rate, as TEE stabilizes thereafter.

If you are starting a calorie restriction diet, your metabolism drops significantly in the first month. To accurately track your progress or adherence, you cannot rely on your starting metabolic rate. You must measure your energy expenditure (or use a proxy like daily home weights) within the first 4 weeks. Ignoring this early drop will make you think you are eating more than you actually are relative to your new metabolic reality.

Regression of daily home body weights over a 4-week period is a valid and reliable method for estimating short-term changes in body energy stores during active weight loss, superior to 2-week body composition changes.

To track your progress accurately during the first few months of a diet, weigh yourself daily at home on a calibrated scale. Do not rely on 2-week body composition scans, as the changes are too small to measure accurately in that timeframe. Instead, use the daily weights to calculate an average trend over 4 weeks.

Weight management interventions delivered by non-medical practitioners (e.g., health coaches) are as effective as those delivered by general practitioners (GPs) or nurses.

You don't need to see a doctor for every weight management visit. Programs led by health coaches or nurses, especially when supervised by a doctor, are just as effective. Focus on finding a program with good support and regular contact.

Tirzepatide treatment in adults with obesity or overweight results in a body composition change where approximately 75% of total weight loss is fat mass and 25% is lean mass, a proportion consistent with placebo and other weight loss modalities.

If you take tirzepatide, expect to lose about 3 pounds of fat for every 1 pound of muscle. This is the same ratio you would get from dieting alone. You do not need to worry that the medication is uniquely damaging to your muscles. To protect your strength, focus on the recommended lifestyle changes: eat 500 calories less per day and move for 150 minutes a week.